We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have recently reviewed TRAVAX Hepatitis B recommendations based on most recent CDC, WHO and Gideon Informatics.
Throughout TRAVAX, Hepatitis B risk is categorised as: High Risk (≥ 8% prevalence) OR Intermediate Risk (2–7% prevalence) OR Low Risk (< 2% prevalence). Every country has a hepatitis B recommendation - see individual country pages.
The drop down Who Should I Vaccinate function is particularly useful when assessing whether to vaccinate against hepatitis B.
1. WHO (2009). Hepatitis B vaccines. WHO Position paper. Weekly Epidemiological Report; 40: 84, 405 – 420. Available at: http://www.who.int/wer/2014/wer8931/en/ [Accessed August, 2015]
2. CDC (2015). CDC Disease Directory; Prevalence of hepatitis B virus infection among adults. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis [Accessed August 2015]. Original Authors: Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine (2012); 30(12): 2212-2219
3. Gideon Informatics Inc. (2015). Hepatitis B; individual country pages. Available at: http://web.gideononline.com/loginy.php?user=scotland [Accessed August, 2015
